<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="998">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04336254</url>
  </required_header>
  <id_info>
    <org_study_id>2020K-G005</org_study_id>
    <secondary_id>hDPSC-CoVID-2019-02-2020</secondary_id>
    <nct_id>NCT04336254</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients</brief_title>
  <official_title>Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19：a Single-center, Prospective, Randomised Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Renmin Hospital of Wuhan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing SH Bio-Tech Corporation, Beijing (CN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Utooth Biological Technology Co., Ltd. Hubei (CN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Renmin Hospital of Wuhan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is set out to evaluate the safety and efficacy of allogeneic human dental
      pulp mesenchymal stem cells in the treatment of severe pneumonia caused by COVID-19; to
      explore the effects of human dental pulp mesenchymal stem cells in the treatment of severe
      pneumonia of COVID-19 in terms of reducing mortality and improving clinical prognosis; and to
      discover a new therapeutic strategy for COVID-19 using allogeneic human dental pulp
      mesenchymal stem cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is set out to evaluate the followings:

        1. the safety and efficacy of allogeneic human dental pulp mesenchymal stem cells in the
           treatment of severe pneumonia caused by COVID-19;

        2. to explore the effects of human dental pulp mesenchymal stem cells in the treatment of
           severe pneumonia of COVID-19 in terms of reducing mortality and improving clinical
           prognosis; and

        3. to discover a new therapeutic strategy for COVID-19 using allogeneic human dental pulp
           mesenchymal stem cells.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 6, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TTCI</measure>
    <time_frame>1-28 days</time_frame>
    <description>Time to Clinical Improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung lesion</measure>
    <time_frame>1-28 days</time_frame>
    <description>Lung Lesion by CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune function</measure>
    <time_frame>1-28 days</time_frame>
    <description>Th1 cytokines: IL-1β, IL- 2, TNF-a, ITN-γ;
Th2 cytokines: IL- 4, IL- 6, IL- 10;
Immunoglobulins: IgA, IgG, IgM, and total IgE;
Lymphocyte counts: CD3+, CD4+, CD8+, CD16+,CD19+, CD56+.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of SARS-CoV-2 clearance</measure>
    <time_frame>1-28 days</time_frame>
    <description>Time of SARS-CoV-2 test turns negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood test</measure>
    <time_frame>1-28 days</time_frame>
    <description>Blood cell count and classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPO2</measure>
    <time_frame>1-28 days</time_frame>
    <description>Pulse oximetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RR</measure>
    <time_frame>1-28 days</time_frame>
    <description>Respiratory rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body temperature</measure>
    <time_frame>1-28 days</time_frame>
    <description>Body temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects in the treatment group</measure>
    <time_frame>1-28 days</time_frame>
    <description>Number of the included patients with hDPSCs-related adverse events, e.g. liver or kidney function failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (mg/L)</measure>
    <time_frame>1-28 days</time_frame>
    <description>C-reactive protein in microgram per litre</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>hDPSCs group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Routine treatment + Intravenous injection of human dental pulp stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Routine treatment + Intravenous saline injection (Placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>allogeneic human dental pulp stem cells (BSH BTC &amp; Utooth BTC)</intervention_name>
    <description>Intravenous injection of 3.0x10e7 human dental pulp stem cells solution (30ml) on day 1, day 4 and day 7, based on routine treatment of COVID-19</description>
    <arm_group_label>hDPSCs group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intravenous saline injection (Placebo)</intervention_name>
    <description>Intravenous injection of 3ml of 0.9% saline on day 1, day 4 and day 7, based on routine treatment of COVID-19</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18-65 years;

          2. Voluntarily participate in this clinical trial and sign off &quot;informed consent form&quot;;

          3. Diagnosed with severe pneumonia of COVID: respiratory distress, RR &gt;30 times / min;
             resting oxygen saturation of 93% or less; arterial partial pressure of oxygen / oxygen
             concentration 300mmHg; SARS-CoV-2 nucleic acid test was positive.

          4. Chest imaging confirm COVID-19 featured lesions in lung.

        Exclusion Criteria:

          1. Receive any clinical trial drug treatment for COVID-2019 within 30 days before the
             screening assessment;

          2. Severe liver disease (e.g., Child Pugh score &gt;=C or AST&gt; 5 times of the upper limit);

          3. Patients with known severe renal insufficiency (estimated glomerular filtration rate
             &lt;=30mL / min/1.73 m2) or patients receiving continuous renal replacement therapy,
             hemodialysis, peritoneal dialysis;

          4. Co-infection of HIV, hepatitis B, tuberculosis, influenza virus, adenovirus or other
             respiratory infection viruses;

          5. Female patients who have no sexual protection in the last 30 days prior to the
             screening assessment;

          6. Pregnant or lactating women or women using estrogen contraception;

          7. Patients who are planning to become pregnant during the study period or within 6
             months after the end of the study period;

          8. Other conditions that the researchers consider not suitable for participating in this
             clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Qingsong Ye, PhD,DDS</last_name>
    <role>Study Chair</role>
    <affiliation>Center for Regenerative Medicine, Renmin Hospital of Wuhan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qingsong Ye, PhD,DDS</last_name>
    <phone>+8615858242516</phone>
    <email>qingsongye@foxmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chenliang Zhou, PhD</last_name>
    <phone>+862788041919</phone>
    <phone_ext>83920</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University (East Campus)</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chenliang Zhou, PhD</last_name>
      <phone>+86 027 88041919</phone>
      <phone_ext>83920</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 28, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Renmin Hospital of Wuhan University</investigator_affiliation>
    <investigator_full_name>Ye Qingsong</investigator_full_name>
    <investigator_title>Professor, Director</investigator_title>
  </responsible_party>
  <keyword>Cronovirus</keyword>
  <keyword>Human Dental Pulp Stem Cells</keyword>
  <keyword>Dental Stem Cell Banking</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

